EUVIMEDEUVIMED entdecken
Crossref

From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs"

Keith L. Carson

BioProcessing Journal · 28.07.2026 · 3

DOI: 10.12665/j161.carson ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioProcessing Journal, online erschienen am 28.07.2026. Verfasst von Keith L. Carson.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

When I go to a therapeutic protein meeting, it’s very hard for me to hear these products referred to as “drugs.” But since they are being regulated by CDER, it’s a little easier to swallow. However, calling viral gene vectors and cellular therapies “drugs” is a bridge too far. My advice to my good friends at CBER is to keep calling their products “biologics,” or they may lose all of their regulatory responsibilities to CDER...

Zitieren

APA

Carson, K. L. (2026). From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs". BioProcessing Journal, 3. https://doi.org/10.12665/j161.carson

Vancouver

Carson KL. From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs". BioProcessing Journal. 2026:3. doi:10.12665/j161.carson

BibTeX
@article{Carson2026,
  author = {Carson, Keith L.},
  title = {From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs"},
  journal = {BioProcessing Journal},
  year = {2026},
  pages = {3},
  doi = {10.12665/j161.carson}
}
Kostenlos starten →